024 Pharma, Inc. (EEIG) SEC Filing 10-Q Quarterly report for the period ending Friday, March 31, 2017

024 Pharma, Inc.

CIK: 1307969 Ticker: EEIG

View differences made from one quarter to another to evaluate 024 Pharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by 024 Pharma, Inc..


Assess how 024 Pharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

024 Pharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

024 Pharma, Inc. provided additional information to their SEC Filing as exhibits

Ticker: EEIG
CIK: 1307969
Form Type: 10-Q Quarterly Report
Accession Number: 0001683168-17-000889
Submitted to the SEC: Tue Apr 11 2017 5:19:29 PM EST
Accepted by the SEC: Tue Apr 11 2017
Period: Friday, March 31, 2017
Industry: Plastics Products

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: